{"id":1014834,"date":"2026-10-28T18:35:42","date_gmt":"2026-10-28T22:35:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/"},"modified":"2026-10-28T18:35:42","modified_gmt":"2026-10-28T22:35:42","slug":"relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/","title":{"rendered":"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass., Oct.  28, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NawAWU8VJifP3vHn4Zbdc9scnh8JtmvHXBxbkzUxqK4CQQ6g4yPOoQ1Nk1lKC9R2XcyeP6T3qvgr-XOlKBmkyPt6-jVENDffQqDVq62JU8o=\" rel=\"nofollow\" target=\"_blank\">Relay Therapeutics, Inc.<\/a> (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report third quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026.<\/p>\n<p>\n        <strong>About Relay Therapeutics<\/strong>\n      <\/p>\n<p>Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing\u00a0potentially life-changing therapies for\u00a0patients living with cancer and genetic disease. Relay Therapeutics\u2019 Dynamo\u00ae platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company\u2019s lead clinical asset,\u00a0zovegalisib, is the first pan-mutant selective PI3K\u03b1 inhibitor to enter clinical development and\u00a0is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+\/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3K\u03b1-driven vascular anomalies. Relay Therapeutics\u2019\u00a0pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5hgO22AcoIcjBp4bsCcixZXmwgv-8iOtz5qFc76yihnQtEK0gLup9NHcs55sBAx0iwvslf4_73OFZs5wvPWgJDHduodo9_llDpAipejalz4=\" rel=\"nofollow\" target=\"_blank\">www.relaytx.com<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HuIjz94GWfI_utnDL4aVfS3FgOK4ywz2qSiOuVPasmrM_1qV0Xx9Oeq0TB4sxet5V1MDqavDk36E7PvQgE28EzEI7KHxjvdkfSe20JuqyxmU-gAh8tj9_3owk4TiTdy4x5vErMOAMZvctfjT5elP3wcr4ads7Yu7JCVnKr1Wplu5t1tL7it38WYWRYbjbIxSxcJnZwWwIKQqxdqfGyt5LQ==\" rel=\"nofollow\" target=\"_blank\">follow us on LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Mitch Maisel<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vqm6sym395CFOXgWk3lY1cCQekgfCBDriITklafTKbZqqkgE6C_gZPZnkag3P7GwYI1GmBTEZrbgCu3sMAbkY9vooGUoeCYHxG7xu5b-aMY=\" rel=\"nofollow\" target=\"_blank\">mmaisel@relaytx.com<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Katie Engleman<br \/>1AB<br \/>919-333-7722<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=79EuwoDQx3K70uAzdD6_B-XOrEfuS8aIzFPw72aNuaQpvSVnSv4KqegkhmAgoYtuo_MS1WNMN1TDUn3ecCDo8DnG2jhbe1XBgB0S-iugmjg=\" rel=\"nofollow\" target=\"_blank\">katie@1abmedia.com<\/a>\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzQ1NDI5ZjMtNmY0ZS00N2YxLThkMTMtOWNmN2RhZTAwOGFkLTEyMTEzMzgtMjAyNi0xMC0yOC1lbg==\/tiny\/Relay-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report third quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing\u00a0potentially life-changing therapies for\u00a0patients living with cancer and genetic disease. Relay Therapeutics\u2019 Dynamo\u00ae platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company\u2019s lead clinical asset,\u00a0zovegalisib, is the first pan-mutant selective PI3K\u03b1 inhibitor to enter clinical development &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1014834","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report third quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing\u00a0potentially life-changing therapies for\u00a0patients living with cancer and genetic disease. Relay Therapeutics\u2019 Dynamo\u00ae platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company\u2019s lead clinical asset,\u00a0zovegalisib, is the first pan-mutant selective PI3K\u03b1 inhibitor to enter clinical development &hellip; Continue reading &quot;Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-28T22:35:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026\",\"datePublished\":\"2026-10-28T22:35:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/\"},\"wordCount\":209,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/\",\"name\":\"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=\",\"datePublished\":\"2026-10-28T22:35:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/","og_locale":"en_US","og_type":"article","og_title":"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report third quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing\u00a0potentially life-changing therapies for\u00a0patients living with cancer and genetic disease. Relay Therapeutics\u2019 Dynamo\u00ae platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company\u2019s lead clinical asset,\u00a0zovegalisib, is the first pan-mutant selective PI3K\u03b1 inhibitor to enter clinical development &hellip; Continue reading \"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-28T22:35:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026","datePublished":"2026-10-28T22:35:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/"},"wordCount":209,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/","name":"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=","datePublished":"2026-10-28T22:35:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTU1MCM3OTIyMDQ0IzIxOTk3ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1014834"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014834\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1014834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1014834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1014834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}